AGTR1
ENSG00000144891
Target class
GPCR
Chromosome
3
Approved drugs
12
Clinical candidates (approved and in development)
19
- Approved drugs
- 12
- Clinical candidates (approved and in development)
- 19
- Chemical probe available
- No
- Target name
- AGTR1
- Gene name
- Angiotensin II receptor type 1
- Gene symbol
- AGTR1
- Previous gene symbols
- AGTR1B
- Protein name
- Type-1 angiotensin II receptor (AT1AR) (AT1BR) (Angiotensin II type-1 receptor) (AT1 receptor)
- AT1
- AT2R1
- AGTR1A
- AT2R1A
- HAT1R
- AG2S
- AT2R1B
- AT1B
- ATR1
- Gene biotype
- Protein coding
- Gene family
- Angiotensin receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 39
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 70.24
- Tissue specificity (Gini)
- 0.644
- Tissue specificity (tau)
- 0.897
- KEGG gene identifiers
- hsa:185
- Protein interaction confidence
- 0.839674
- Protein interaction partners
- 46
- R-HSA-375276
- R-HSA-416476
- R-HSA-8856825
- R-HSA-8856828
- End position
- 148743045
- Start position
- 148697784
- Chromosome
- 3
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- PubMed 33713620
- PubMed 25913193
- PubMed 26420482
- PubMed 30639100
- PubMed 32079768
- Tissue specificity (tau)
- 0.896992
- Expression inequality (Gini)
- 0.644408
Expression in transcripts per million
- Adipose - Subcutaneous
- 70.24
- Breast - Mammary Tissue
- 39
- Adipose - Visceral (Omentum)
- 34.33
- Adrenal Gland
- 33.7
- Liver
- 27.97
Expression in transcripts per million
- Adipose - Subcutaneous70.24
- Breast - Mammary Tissue39
- Adipose - Visceral (Omentum)34.33
- Adrenal Gland33.7
- Liver27.97
- Colon - Sigmoid23.62
- Thyroid18.13
- Bladder15.36
- Skin - Sun Exposed (Lower leg)14.4
- Artery - Tibial13.57
- Lung12.96
- Nerve - Tibial12.37
- Fallopian Tube11.01
- Esophagus - Gastroesophageal Junction10.84
- Esophagus - Muscularis8.86
- Artery - Coronary8.74
- Colon - Transverse7.6
- Skin - Not Sun Exposed (Suprapubic)6.79
- Heart - Atrial Appendage5.87
- Cells - Cultured fibroblasts5.57
- Kidney - Cortex5.55
- Uterus5.5
- Artery - Aorta5.45
- Spleen5.37
- Kidney - Medulla5.07
And 29 more, listed on the interactive page.
- GO:0001822
- GO:0002034
- GO:0003081
- GO:0007186
- GO:0007200
- GO:0007204
- GO:0007266
- GO:0010744
- GO:0019229
- GO:0019722
- GO:0038166
- GO:0046718
- GO:0050727
- GO:0050729
- GO:0060326
- GO:0086097
- GO:0090205
- GO:0097746
- GO:1903589
- GO:2000379
Cellular components
- GO:0005886
- GO:0001596
- GO:0004945
- GO:0005515
- GO:0031711
- GO:0046982
increased pain
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased pain
- renal
- cardiovascular
PubMed 28216264respiratory distress syndrome
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: respiratory distress syndrome
- renal
- cardiovascular
PubMed 28216264excessive thirst
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: excessive thirst
Biological samples
- cardiovascular system
Evidence sourcedry mouth
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: dry mouth
Biological samples
- cardiovascular system
Evidence sourcehypocalvaria
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: hypocalvaria
- renal
- cardiovascular
PubMed 28216264oligoamnios
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: oligoamnios
- renal
- cardiovascular
PubMed 28216264cerebral complications
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: cerebral complications
- renal
- cardiovascular
PubMed 28216264slow or irregular heartbeat
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: slow or irregular heartbeat
Biological samples
- cardiovascular system
Evidence sourcecell proliferation and migration
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: cell proliferation and migration
Biological samples
- cardiovascular system
Evidence sourcepersistent patent ductus arteriosus
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: persistent patent ductus arteriosus
- renal
- cardiovascular
PubMed 28216264renal failure
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: renal failure
- renal
- cardiovascular
PubMed 28216264increased/decreased urine excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased/decreased urine excretion
- renal
- cardiovascular
PubMed 28216264antihypertensive and cardioprotective agent
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: antihypertensive and cardioprotective agent
Biological samples
- cardiovascular system
Evidence sourceincreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased blood pressure
- renal
- cardiovascular
PubMed 28216264positive inotropy
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: positive inotropy
Biological samples
- cardiovascular system
Evidence sourcedecreased blood pressure
- Inhibition/Decrease/Downregulation: developmental toxicity
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased blood pressure
- renal
- cardiovascular
PubMed 28216264decreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pain
- renal
- cardiovascular
PubMed 28216264hypotension
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: hypotension
Biological samples
- cardiovascular system
Evidence sourcedizziness
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: dizziness
Biological samples
- cardiovascular system
Evidence sourcepulmonary hypoplasia
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: pulmonary hypoplasia
- renal
- cardiovascular
PubMed 28216264intrauterine growth retardation
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: intrauterine growth retardation
- renal
- cardiovascular
PubMed 28216264increased/decreased urinary sodium excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased/decreased urinary sodium excretion
- renal
- cardiovascular
PubMed 28216264decreased urinary sodium excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased urinary sodium excretion
- renal
- cardiovascular
PubMed 28216264death
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: death
- renal
- cardiovascular
PubMed 28216264vasocontriction
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: vasocontriction
Biological samples
- cardiovascular system
Evidence source
And 1 more, listed on the interactive page.
receptor binding
Studies
- biochemical: NVS_GPCR_hAT1, is one of one assay component(s) measured or calculated from the NVS_GPCR_hAT1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- brain, tissue-based cell-free
Evidence source
Related records
Trials (1,514)
- : Vascular Function in Health and Disease
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
- 1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
- 18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics
- 24 Hour Ambulatory Cardiac Oxygen Consumption
- 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension
- 8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension
- 8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension
- A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
- A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome
- A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)
- A Bioequivalence Study Between Telmione 80 mg and Micardis 80 mg in Healthy Adult Volunteers
- A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers
- A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination Tablet With Coadministration of Cilnidipine and Valsartan
- A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan
- A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin
- A Bioequivalence Study of Amlodipine / Valsartan From Amlodipine/Valsartan 10/160 Tablets (Pharmacare, Palestine) and Exforge Tablets (Novartis Pharma, USA)
- A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan
- A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan
- A Bioequivalence Study of Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) in Normal, Healthy, Adults Under Fasting Conditions
Drugs (24)
- Angiotensin II Type-1 angiotensin II receptor agonist
- Angiotensin II acetate Type-1 angiotensin II receptor agonist
- Azilsartan Type-1 angiotensin II receptor antagonist
- Azilsartan kamedoxomil Type-1 angiotensin II receptor antagonist
- Azilsartan medoxomil Type-1 angiotensin II receptor antagonist
- Candesartan Type-1 angiotensin II receptor antagonist
- Candesartan cilexetil Type-1 angiotensin II receptor antagonist
- Eprosartan Type-1 angiotensin II receptor antagonist
- Eprosartan mesylate Type-1 angiotensin II receptor antagonist
- Fimasartan Type-1 angiotensin II receptor antagonist
- Irbesartan Type-1 angiotensin II receptor antagonist
- Irbesartan hydrochloride Type-1 angiotensin II receptor antagonist
- Losartan Type-1 angiotensin II receptor antagonist
- Losartan potassium Type-1 angiotensin II receptor antagonist
- Olmesartan Type-1 angiotensin II receptor antagonist
- Olmesartan medoxomil Type-1 angiotensin II receptor antagonist
- Pratosartan Type-1 angiotensin II receptor antagonist
- Saralasin Type-1 angiotensin II receptor antagonist
- Saralasin acetate Type-1 angiotensin II receptor antagonist
- Sparsentan Type-1 angiotensin II receptor antagonist